Preliminary results from pralsetinib have shown a 60% ORR and 18-month duration of response rate of 90% in previously treated RET-mutant MTC, as well as a 74% ORR in treatment-naïve RET-mutant MTC patients [107]. Here, RET is linked to medullary thyroid gland carcinoma.